Ophthotech

Ophthotech Corporation, based in Newton Center, MA, focuses on discovering and developing innovative therapeutics and gene therapy solutions to address ophthalmic diseases, particularly orphan and age-related retinal diseases such as age-related macular degeneration (AMD). The company has made significant strides in advancing treatment options for AMD, with its leading product, Fovista, showing a 62% improvement in vision compared to baseline measurements when contrasted with anti-VEGF monotherapy.

With a dedicated management team and a distinguished Scientific Advisory Board, Ophthotech is committed to enhancing patient outcomes and alleviating the burden of AMD on healthcare systems. The company's research efforts are underscored by a strong emphasis on clinical trials and collaboration with leading experts in the field of ophthalmology.

Generated from the website